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Results: All patients demonstrated on-treatment reduction in 
MRI-defined GTV (Figure 1). Average reduction in tumor size 
from treatment initiation to completion of therapy was 51.0% 
(median 52.1%) and ranged from 30.5-70.8%. At a time point 
of fraction six, average reduction in GTV size was 38.2% 
(median 34.8%). Linear correlation across median values at 
each time point suggested a consistent decline over time of 
approximately 4% per day, with the most pronounced changes 
occurring between the 5th and 6th fractions. 
 
 
 
Conclusion: Tumor volume decreased considerably during 
treatment for most patients undergoing lung SBRT. The 
dosimetric impact of this degree of MRI-defined tumor 
volume change during the course of therapy has yet to be 
assessed. However, adaptive planning during the course of 
SBRT may be dosimetrically advantageous for sparing of 
surrounding critical structures, particularly for disease 
involving the central thorax. 
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Purpose or Objective: Non-small cell lung cancer has a 
substantial impact on health-related quality of life (HRQoL) 
of affected patients. Measuring HRQoL in lung cancer 
patients is an important approach to forecast and assess the 
relative risks and benefits of a treatment as experienced by 
patients. A systematic literature review was performed to 
provide an overview of prospective studies measuring HRQoL 
in patients with locally-advanced non-small lung cancer (LA-
NSCLC) receiving treatment with curative intent, published 
over the last 10 years.  
 
Material and Methods: The literature search was performed 
in four electronic databases: PubMed, ScienceDirect, 
MEDLINE and Embase. The inclusion criteria for the studies 
were: English language, clinical trial, study population with 
LA-NSCLC, treatment with curative intent, HRQoL 
assessment, full text availability and published over the last 
10 years.  
 
Results: Only 5 studies out of the 225 potentially eligible 
studies matched our inclusion criteria. Four of these were 
randomized controlled trials; one was a prospective cohort 
study. All studies included radiotherapy at least in one of the 
evaluated treatment arms. Details of the studies and the 
analyzed parameters are shown in the table. HRQoL was a 
secondary endpoint in four studies and a co-primary endpoint 
in one. No significant treatment-related improvement or 
deterioration in HRQoL has been reported in the included 
studies. Variability has been observed in terms of use of 
HRQoL instruments and statistical analysis.  
 
Conclusion: Evaluation of HRQoL in patients with LA-NSCLC 
receiving curative intent treatment remains scarce. 
Reporting and statistical analysis of HRQoL data lacks 
standardization. More research is needed to address these 
issues in both clinical trials and daily care of patients 
receiving radiotherapy as part of their primary treatment for 
LA-NSCLC. Based on these considerations, a prospective 
cohort study has been launched in our institute, which aims 
to evaluate HRQoL, treatment-induced toxicity and 
neurocognitive functioning in patients with unresectable LA-
NSCLC receiving radiotherapy, all or not in combination with 
concurrent or sequential chemotherapy.  
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Purpose or Objective: To evaluate clinical outcomes of 
salvage radiotherapy for regional lymph node (LN) recurrence 
developing after radical surgery of non-small cell lung cancer 
(NSCLC). 
 
Material and Methods: Between 2008 and 2013, out of 
patients with NSCLC who achieved complete response (CR) 
after definitive treatment (surgery with or without 
chemotherapy), 31 patients developed regional LN 
(mediastinum, hilum, and supraclavicular area) recurrence 
(median age, 66 years; stage Ⅰ, n = 17; stage Ⅱ, n = 7; stage 
ⅢA, n = 7). The median time from definitive surgery to 
recurrence was 12 months (range, 3-80). Fifteen patients 
(48.4%) had single LN recurrence and others had multiple LN 
recurrence. All patients were irradiated to the recurred LN 
area with daily fractions of 2.0 Gy (n = 27), 2.5 Gy (n = 2), or 
3.0 Gy (n = 2) by 3D-conformal radiotherapy. The median 
total dose for recurred LN was 66 Gy (BED 79.2 Gy10; range, 
65.1-79.2 Gy10). Sixteen patients received chemotherapy 
either. 
 
Results: The median follow-up was 14 months (range, 3-76). 
After salvage radiotherapy, 16 patients (51.6%) achieved CR, 
9 patients (29.0%) partial response, and 6 patients (19.4%) 
stable disease. After salvage radiotherapy, one- and two-year 
in-field local control rate was 88.4% and 75.8%, respectively. 
Only two patients experienced an out-of-field mediastinal 
recurrence. One- and two-year progression-free survival rate 
from initial salvage radiotherapy was 73.1% and 50.9%, 
respectively. Progression site was predominantly distant. 
Overall, ten of 31 patients (32.3%) were successfully salvaged 
as CR state. Recurred LN size (<3 vs. ≥3 cm) was a significant 
prognostic factor for progression-free survival (p = 0.03). 
Pneumonitis requiring conservative treatment (grade 2 or 
more) occurred in 5 patients (16.1%). There was no radiation-
related mortality. 
 
Conclusion: Salvage radiotherapy for regional LN recurrence 
after radical surgery was suggested to be an effective 
treatment option with an acceptable level of toxicity. The 
recurred node size (3 cm cutoff value) was a strong predictor 
of progression-free survival. Aggressive salvage radiotherapy 
should be considered as a front-line treatment in regional LN 
recurrence of NSCLC. 
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Purpose or Objective: To compare patterns of acute and 
late clinical/radiological lung toxicity following either 3D or 
image-guided VMAT stereotactic radiotherapy for stage I non-
small cell lung cancer (NSCLC). 
 
Material and Methods: In this observational study, we 
included 148 patients from a prospective mono-institutional 
SBRT series (time interval 2004-2014). All subjects had 
peripheral tumors and a prescription BED10Gy (at 80%) in the 
range 100-120 Gy. The first 95 patients (2004-2010) were 
planned with 3D-CRT, using multiple non-coplanar fields; a 
stereotactic body frame was used with CTV-PTV margins of 5 
mm (antero-posterior and latero-lateral) and 10 mm (cranio-
caudal). The second cohort (2010-2014) included 53 patients, 
planned with volumetric IMRT, using a single/multi arcs VMAT 
technique, on a PTV generated with 3 mm margins from a 
patient’s specific ITV (obtained from 4D-CT), with a 
frameless approach through cone-beam CT guidance. Clinical 
acute and late toxicities were scored according to RTOG 
scales; radiological acute (<6 months from SBRT) and late (>6 
months post SBRT) toxicity on the basis of modified Kimura 
and Koenig’s classifications, respectively. Student’s T test 
was used to compare clinical characteristics, and Pearson’s 
chi square test to compare the incidence of any grade lung 
toxicity. 
 
Results: Patients and tumors’ characteristics were similar 
and well matched between the groups. PTV volumes were 
also comparable (35.1 cc for 3D-CRT vs. 40.3 cc for VMAT,, 
p=0.16). Moreover, no significant difference was detected in 
Mean Lung Dose, converted in 2 Gy equivalent (11.7 vs. 10.4 
Gy for 3D-CRT and VMAT, respectively, p=0.13). Frequencies 
of acute and late clinical toxicity (all grades) were 
superimposable between 3D-CRT and VMAT (acute: 10.5% vs. 
22.6%, p=0.28; late: 4.2% vs. 13%, p=0.09, respectively). The 
crude rate of RTOG acute ≥ grade 3 radiation pneumon itis 
was 2.1% after 3D-CRT and 3.8% after VMAT. Acute and late 
radiological toxicity patterns were also similar between the 
two cohorts. Figures 1 and 2 depict the incidence and grade 
of both, according to different treatments. As expected, late 
radiological toxicity occurred in approximately 60% of 
patients, with modified conventional (25% after 3D-CRT vs. 
32.6% after VMAT) and mass-like (19.6% after 3D-CRT vs. 
17.4% after VMAT) patterns as the most commonly observed 
findings. 
 
 
 
 
Conclusion: Results of the present study indicate that the 
pattern of clinical and radiological toxicities following SBRT 
in peripheral early stage NSCLC treated with comparable 
BED10Gy is not influenced by the different techniques used 
for planning and delivery. 
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Purpose or Objective: Inoperable non-small cell lung cancer 
(NSCLC) comprises several histological subtypes, with 
squamous cell carcinoma (SCC) and adenocarcinoma (AC) 
being most frequent. The prognosis is poor with current 
chemo-radiation strategies and treatment intensification is 
limited by patient tolerance. It is therefore relevant to target 
experimental therapeutic approaches to a patient's risk of 
local versus distant failure. The purpose of the current study 
was to compare the pattern of first relapse after chemo-
radiation for locally advanced pulmonary SCC and AC. 
 
Material and Methods: We retrospectively included 193 
patients with locally advanced NSCLC treated with chemo-
radiotherapy from 2009 to 2012. Patients with initial stage IV 
(n=17) disease and/or patients with histology other than AC 
or SCC (n=22) were excluded leaving 155 patient for the 
analysis. Patients were identified and grouped according to 
first event as either: loco-regional (LR) failure; intra-cranial 
distant metastases (ICDM), extra-cranial distant metastases 
(ECDM); dead without evidence of disease (Dead, NED), with 
the remaining patients being Alive, NED at latest follow-up in 
August 2015. The cumulative incidence of events was 
compared across the histology subtypes, using the competing 
risk method of Fine and Gray. 
 
 
 
